Bladder Cancer Vaccine
Moureau-Rio de Janeiro BCG strain reduces recurrence rate in bladder cancer
Published in Vaccine Weekly, December 21st, 2005
According to researchers in Brazil, "We present our experience with lyophilized Moureau-Rio de Janeiro BCG strain for treatment of patients with recurrent superficial bladder cancer."
"From October 1986 to January 2001, 114 patients were treated by transurethral resection followed by intravesical instillation of BCG at our institution. Follow-up ranged from 10 to 144 months (mean 50.16 months). The treatment included 6 inductions and 10 maintenance cycles of BCG instillations. The patients received an initial dose with 40 mg and subsequent doses with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-12-21)
More Articles from Vaccine Weekly
- Addiction Medicine
Immunotherapy for treatment of drug abuse is reviewed - Adenovirus Vaccine
Adenovirus serotypes 4 and 7 vaccine strains were sequenced and compared - Gastroenteritis Vaccine
Shiga toxin subunit::rotavirus fusion protein protects against gastroenteritis - Yellow Fever Vaccine
New developments in flavivirus vaccines are reviewed - Adenovirus Vectors
Infectious mutants accumulate in stocks during propagation of adenoviruses - Adenovirus Vectors
Peptide-presenting libraries allow choice of peptide ligands for viral vector retargeting - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
